Regeneron Pharmaceuticals Inc.’s (REGN) Biologics License Application for Odronextamab is under priority review by the FDA, with a decision due on March 31, 2024. Odronextamab, an investigational CD20xCD3 bispecific antibody, is proposed for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies.If approved, Odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma.REGN closed Tuesday's (Feb.27, 2024) trading at $993.35, up 0.41%.